The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Balchem's revenues will grow 9.0% and EPS will grow 19.4%.
The average estimate for revenue is $83.1 million. On the bottom line, the average EPS estimate is $0.37.
Last quarter, Balchem tallied revenue of $80.1 million. GAAP reported sales were 15% higher than the prior-year quarter's $69.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.33. GAAP EPS of $0.33 for Q4 were 6.5% higher than the prior-year quarter's $0.31 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 28.0%, 190 basis points worse than the prior-year quarter. Operating margin was 18.8%, 80 basis points worse than the prior-year quarter. Net margin was 12.4%, 120 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $340.7 million. The average EPS estimate is $1.60.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 343 members out of 351 rating the stock outperform, and eight members rating it underperform. Among 90 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 89 give Balchem a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Balchem is outperform, with an average price target of $37.33.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Balchem to My Watchlist.